Corcept Therapeutics Faces Investigation Over FDA Drug Application

Berman Tabacco, a national law firm, is investigating potential securities law violations by the pharmaceutical company.

Jan. 30, 2026 at 2:23pm

Got story updates? Submit your updates here. ›

Berman Tabacco, a national law firm representing investors, has announced an investigation into potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT), a pharmaceutical company based in Redwood City, California. The investigation follows Corcept's announcement on December 31, 2025, that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter regarding the company's New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.

Why it matters

The investigation by Berman Tabacco could have significant implications for Corcept Therapeutics, as the firm has a history of successfully prosecuting securities cases on behalf of investors. The outcome of the investigation could impact the company's stock price and public perception, as well as potentially lead to legal action or regulatory scrutiny.

The details

According to the press release, Corcept stated that it was 'surprised and disappointed' by the FDA's decision. On January 30, 2026, Reuters reported that Corcept's stock fell 16% after a corrected 'complete response letter' from the FDA showed the agency had warned the company 'on several occasions' not to submit its drug application.

  • On December 31, 2025, Corcept issued a press release announcing the FDA's Complete Response Letter.
  • On January 30, 2026, Reuters reported on the corrected 'complete response letter' from the FDA.

The players

Corcept Therapeutics Incorporated

A pharmaceutical company based in Redwood City, California that is under investigation by Berman Tabacco for potential securities law violations.

Berman Tabacco

A national law firm representing investors that is conducting the investigation into Corcept Therapeutics.

U.S. Food and Drug Administration (FDA)

The federal agency that issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, which has led to the investigation by Berman Tabacco.

Got photos? Submit your photos here. ›

The takeaway

The investigation by Berman Tabacco into Corcept Therapeutics highlights the potential legal and regulatory risks facing pharmaceutical companies when seeking FDA approval for new drugs. The outcome of this investigation could have significant implications for Corcept's future and serve as a cautionary tale for other companies navigating the complex drug approval process.